TY  - JOUR
AU  - Quenon, Lisa
AU  - Collij, Lyduine E
AU  - Garcia, David Vállez
AU  - Lopes Alves, Isadora
AU  - Gérard, Thomas
AU  - Malotaux, Vincent
AU  - Huyghe, Lara
AU  - Gispert, Juan Domingo
AU  - Jessen, Frank
AU  - Visser, Pieter Jelle
AU  - den Braber, Anouk
AU  - Ritchie, Craig W
AU  - Boada, Mercè
AU  - Marquié, Marta
AU  - Vandenberghe, Rik
AU  - Luckett, Emma S
AU  - Schöll, Michael
AU  - Frisoni, Giovanni B
AU  - Buckley, Christopher
AU  - Stephens, Andrew
AU  - Altomare, Daniele
AU  - Ford, Lisa
AU  - Birck, Cindy
AU  - Mett, Anja
AU  - Gismondi, Rossella
AU  - Wolz, Robin
AU  - Grootoonk, Sylke
AU  - Manber, Richard
AU  - Shekari, Mahnaz
AU  - Lhommel, Renaud
AU  - Dricot, Laurence
AU  - Ivanoiu, Adrian
AU  - Farrar, Gill
AU  - Barkhof, Frederik
AU  - Hanseeuw, Bernard J
TI  - Amyloid-PET imaging predicts functional decline in clinically normal individuals.
JO  - Alzheimer's research & therapy
VL  - 16
IS  - 1
SN  - 1758-9193
CY  - London
PB  - BioMed Central
M1  - DZNE-2024-00779
SP  - 130
PY  - 2024
AB  - There is good evidence that elevated amyloid-β (Aβ) positron emission tomography (PET) signal is associated with cognitive decline in clinically normal (CN) individuals. However, it is less well established whether there is an association between the Aβ burden and decline in daily living activities in this population. Moreover, Aβ-PET Centiloids (CL) thresholds that can optimally predict functional decline have not yet been established.Cross-sectional and longitudinal analyses over a mean three-year timeframe were performed on the European amyloid-PET imaging AMYPAD-PNHS dataset that phenotypes 1260 individuals, including 1032 CN individuals and 228 participants with questionable functional impairment. Amyloid-PET was assessed continuously on the Centiloid (CL) scale and using Aβ groups (CL < 12 = Aβ-, 12 ≤ CL ≤ 50 = Aβ-intermediate/Aβ± , CL > 50 = Aβ+). Functional abilities were longitudinally assessed using the Clinical Dementia Rating (Global-CDR, CDR-SOB) and the Amsterdam Instrumental Activities of Daily Living Questionnaire (A-IADL-Q). The Global-CDR was available for the 1260 participants at baseline, while baseline CDR-SOB and A-IADL-Q scores and longitudinal functional data were available for different subsamples that had similar characteristics to those of the entire sample.Participants included 765 Aβ- (61
KW  - Humans
KW  - Positron-Emission Tomography: methods
KW  - Female
KW  - Male
KW  - Cross-Sectional Studies
KW  - Longitudinal Studies
KW  - Aged
KW  - Amyloid beta-Peptides: metabolism
KW  - Activities of Daily Living
KW  - Cognitive Dysfunction: diagnostic imaging
KW  - Cognitive Dysfunction: metabolism
KW  - Middle Aged
KW  - Brain: diagnostic imaging
KW  - Brain: metabolism
KW  - Aged, 80 and over
KW  - Amyloid-PET (Other)
KW  - Centiloid (Other)
KW  - Functional decline (Other)
KW  - Instrumental activities of daily living (Other)
KW  - Preclinical Alzheimer (Other)
KW  - Amyloid beta-Peptides (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C2  - pmc:PMC11181677
C6  - pmid:38886831
DO  - DOI:10.1186/s13195-024-01494-9
UR  - https://pub.dzne.de/record/270307
ER  -